Triple Giving November OMF logo

 TRIPLE YOUR IMPACT during Triple Giving November | All Donations to OMF are TRIPLED through December 3

Search
Close this search box.

Autoimmunity and Autoantibodies in ME/CFS

Investigate potential differences in adrenergic and muscarinic receptor autoantibody levels in plasma and cerebrospinal fluid (CSF) samples between ME/CFS patients and healthy controls, examine why these autoantibodies start to show up in the disease process and how we might positively impact this process with various drug targets and immune regulatory treatments. Being able to explain these underlying mechanisms may provide the validation needed for specific ongoing treatments.

  • Jonas Bergquist, MD, PhD
  • Annie Bynke, Med Student, PhD
  • Per Julin, MD, PhD
  • CG Gottfries, MD, PhD
  • Carmen Scheibenbogen, MD, PhD
STUDY HYPOTHESIS AND DESCRIPTION

The development of autoimmune antibodies is a consistent finding across HSE, ME/CFS, Long COVID and provide a window into the neurocognitive disturbances, peripheral symptoms, POTS, pain, and other targets of these autoantibodies.

Previously, autoantibodies have been observed to have increased binding to adrenergic and muscarinic receptors in ME/CFS patients. It is hypothesized

that these autoantibodies may be part of the pathogenesis of ME/CFS and patient symptom.

OBJECTIVES

  • Investigate potential differences in adrenergic and muscarinic receptor autoantibody levels in plasma and cerebrospinal fluid (CSF) samples between ME/CFS patients and healthy controls.
  • Combine these findings with ME/CFS patients and contrast groups (including such as Long COVID, critical COVID patients, neuroimmunology induced cognitive dysfunction patients).
  • Evaluate data to identify potential differences and patient subgroups.

 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.


How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669